hero image

Richard A. Rudick Joins Biogen Idec as Vice President, Development Sciences, Value-Based Medicine

May 12, 2014 Corporate

– Renowned Neurologist and MS Researcher to Lead Value-Based Medicine Group in New Role –


CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen Idec (NASDAQ: BIIB) today announced that Richard (Rick) A. Rudick, M.D., has joined the company as vice president, Development Sciences, Value-Based Medicine.

Dr. Rudick will lead Biogen Idec’s newly created Value-Based Medicine Group, which will focus on using new technology to develop innovative programs and tools to better understand, measure and manage the treatment of multiple sclerosis (MS). These assets are intended to enable physicians and patients to make more evidence-based, individualized treatment decisions with the goal of improving MS care. He will report to Alfred Sandrock, M.D., Ph.D., group senior vice president and chief medical officer.

“Rick has been a valued partner of the company for more than two decades. Through his years of hands-on clinical experience, he has gained a truly unique understanding of the needs of MS patients,” said Dr. Sandrock. “His vision, expertise and passion bolsters our efforts to create real-world, practical solutions to empower better decision-making and improve the way people live with MS.”

As an internationally recognized clinical researcher and thought leader in the MS field, Dr. Rudick has played key roles in several MS clinical trials, including the pivotal clinical trials of Biogen Idec’s products, AVONEX® (interferon beta-1a) and TYSABRI® (natalizumab).

“While current therapies are effective at controlling the progression of MS and improving symptoms, we need to better understand the real-world patient experience in a consistent and rigorous way to optimize individual treatment outcomes,” said Dr. Rudick. “By developing the right tools and models, we believe we can bridge the gap between investigational and real-world treatment, and improve the overall patient experience.”

Dr. Rudick joins Biogen Idec from the Cleveland Clinic, where he served as director of the Mellen Center for Multiple Sclerosis Treatment and Research for nearly 30 years. He also served as professor of Medicine at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, the Hazel Prior Hostetler chair of Neurology, and vice chairman of Research and Development in the Neurological Institute at Cleveland Clinic.

Dr. Rudick has lectured and consulted on clinical research programs in MS around the world and maintained a consultative clinical practice at the Mellen Center. Dr. Rudick also maintained continuous competitive grant funding from the National Institutes of Health (NIH) and the National Multiple Sclerosis Society (NMSS) for more than 25 years, led studies on immunologic changes in MS patients, and developed new clinical and imaging measures for MS clinical trials. Dr. Rudick graduated from Case Western Reserve University School of Medicine in 1975.

About Biogen Idec

Through cutting-edge science and medicine, Biogen Idec discovers, develops and delivers to patients worldwide innovative therapies for the treatment of neurodegenerative diseases, hemophilia and autoimmune disorders. Founded in 1978, Biogen Idec is the world’s oldest independent biotechnology company. Patients worldwide benefit from its leading multiple sclerosis therapies. For product labeling, press releases and additional information about the Company, please visit www.biogenidec.com.

Safe Harbor

This press release contains forward-looking statements, including statements about advances and improvements that may be achieved from our technology development efforts. These statements may be identified by words such as "believe," "expect," "may," "plan," "potential," "will" and similar expressions, and are based on current beliefs and expectations. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including risks and uncertainties relating to the development and acceptance of new products and tools, as well as other risks and uncertainties that are described in the Risk Factors section of our most recent annual or quarterly report filed with the U.S. Securities and Exchange Commission. Any forward-looking statements speak only as of the date of this press release and we assume no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.




Biogen Idec
Kate Niazi-Sai, +1-781-464-3260
Biogen Idec
Benjamin Strain, +1-781-464-2442



May 16, 2024
Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis

Development of BIIB105, an investigational antisense oligonucleotide for amyotrophic lateral sclerosis (ALS), will be discontinued based on data from the Phase 1/2 ALSpire study Biogen and Ionis continue their long-standing commitment to developing therapies for ALS given the devastating impact of

May 14, 2024
Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Under the Fast Track Status

TOKYO and CAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that Eisai has initiated the